Cetera Investment Advisers grew its holdings in Bruker Co. (NASDAQ:BRKR – Free Report) by 2.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,936 shares of the medical research company’s stock after buying an additional 805 shares during the quarter. Cetera Investment Advisers’ holdings in Bruker were worth $2,165,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in BRKR. Lifestyle Asset Management Inc. raised its position in Bruker by 1.3% during the first quarter. Lifestyle Asset Management Inc. now owns 12,534 shares of the medical research company’s stock worth $1,177,000 after acquiring an additional 158 shares during the period. Nisa Investment Advisors LLC lifted its stake in Bruker by 20.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 991 shares of the medical research company’s stock valued at $63,000 after buying an additional 165 shares in the last quarter. Securian Asset Management Inc. lifted its stake in Bruker by 2.3% in the 2nd quarter. Securian Asset Management Inc. now owns 7,766 shares of the medical research company’s stock valued at $496,000 after buying an additional 175 shares in the last quarter. Park Place Capital Corp boosted its holdings in Bruker by 19.4% in the 1st quarter. Park Place Capital Corp now owns 1,139 shares of the medical research company’s stock worth $107,000 after buying an additional 185 shares during the last quarter. Finally, Covestor Ltd increased its stake in Bruker by 139.1% during the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock worth $34,000 after buying an additional 210 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on BRKR. Wolfe Research lowered Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. The Goldman Sachs Group reduced their target price on shares of Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research report on Tuesday, July 9th. Citigroup decreased their price target on shares of Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday, July 10th. TD Cowen cut their price objective on shares of Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a report on Wednesday, August 7th. Finally, Wells Fargo & Company assumed coverage on Bruker in a report on Tuesday, August 27th. They set an “overweight” rating and a $78.00 target price on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $81.40.
Bruker Trading Up 1.3 %
BRKR opened at $64.54 on Friday. The stock has a market capitalization of $9.38 billion, a PE ratio of 23.47, a P/E/G ratio of 2.52 and a beta of 1.18. Bruker Co. has a one year low of $53.79 and a one year high of $94.86. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.75 and a current ratio of 1.65. The business’s 50 day moving average price is $65.12 and its 200 day moving average price is $70.09.
Bruker (NASDAQ:BRKR – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.52. The business had revenue of $800.70 million during the quarter, compared to analysts’ expectations of $799.44 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. The company’s revenue was up 17.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.50 EPS. As a group, equities research analysts expect that Bruker Co. will post 2.61 EPS for the current year.
Bruker Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Monday, September 2nd were issued a $0.05 dividend. The ex-dividend date was Friday, August 30th. This represents a $0.20 annualized dividend and a dividend yield of 0.31%. Bruker’s dividend payout ratio is currently 7.27%.
About Bruker
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Read More
- Five stocks we like better than Bruker
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- What is a Death Cross in Stocks?
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.